TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25304965

Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ice application
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intravenous paracetamol
Number of subjects: 130
Study: 23610448

Group type: EXPERIMENTAL
Intervention: Sunitinib (oral antiangiogenic tyrosine kinase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pazopanib (oral antiangiogenic tyrosine kinase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DC101 (antibody targeting the VEGF pathway)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 0
Study: 21931738

Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham feedback from the left horizontal segment of the intraparietal sulcus (HIPS)
Number of subjects: 0
Study: 17964811

Group type: EXPERIMENTAL
Intervention: Agent with open eyes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agent with sunglasses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agent with closed eyes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agent with occluders
Number of subjects: 0
Study: 16537725

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily for up to 8 days
Number of subjects: 12092
Study: 12750950

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus domperidone
Number of subjects: 953

Group type: COMPARATOR
Intervention: Sennoside calcium
Number of subjects: 953

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) lavage
Number of subjects: 953

Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP) in one 90‐ml dose
Number of subjects: 953

Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP) in 2 doses (90 ml + 45 ml)
Number of subjects: 953

Group type: COMPARATOR
Intervention: Oral sodium phosphate (NaP) in 2 doses (45 ml + 90 ml) plus cisapride
Number of subjects: 953
Study: 10977009

Group type: EXPERIMENTAL
Intervention: 3 g American ginseng (AG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0 g (placebo)
Number of subjects: 10
Study: 9125030

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 62

Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 62
Study: 8477178

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of oxitropium and fenoterol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29897351

Group type: EXPERIMENTAL
Intervention: Group A (KM ≥ 2 mm)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group B (KM < 2 mm)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 30243811

Group type: EXPERIMENTAL
Intervention: Square-Stepping Exercise (SSE) program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Minimal activity, attention-control condition
Number of subjects: 26
Study: 27342494

Group type: EXPERIMENTAL
Intervention: Lenalidomide + chemotherapy (LC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy + placebo (CP)
Number of subjects: 0
Study: 24894533

Group type: EXPERIMENTAL
Intervention: Tamsulosin plus tadalafil (group B)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Tamsulosin (group A)
Number of subjects: 244
Study: 22201336

Group type: EXPERIMENTAL
Intervention: Low dose etizolam for 2 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 73
Study: 17142005

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CF) with ropivacaine 0.2%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intravenous propacetamol (P) 2 g every 6 hours
Number of subjects: 62

Group type: COMPARATOR
Intervention: Subcutaneous morphine (M) 0.05 mg/kg every 4 hours
Number of subjects: 62
Study: 16143283

Group type: EXPERIMENTAL
Intervention: Single transplanted lung
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External intercostal and external oblique muscles on the side of the transplanted lung
Number of subjects: 0
Study: 12142304

Group type: EXPERIMENTAL
Intervention: Prescribed graded aerobic exercise
Number of subjects: 132

Group type: COMPARATOR
Intervention: Relaxation and flexibility (control treatment)
Number of subjects: 132
Study: 10215768

Group type: EXPERIMENTAL
Intervention: ABL 0.1% in white soft paraffin applied twice daily for 2 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1.0 microg/mL ABL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 3.0 microg/mL ABL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 microg/mL ABL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1.0 microg/mL ABL for 8 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Topical application of ABL 0.01% or 0.1%
Number of subjects: 11
Study: 7554017

Group type: EXPERIMENTAL
Intervention: Breast-feeding training course at SLC (18-day course)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no training course)
Number of subjects: 8
Study: 2182960

Group type: EXPERIMENTAL
Intervention: Confidence Profile Method
Number of subjects: 0
Study: 468096

Group type: EXPERIMENTAL
Intervention: Gastropulgit Tabs (2 tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (640 mg)
Number of subjects: 0
Study: 30184165

Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF (Doravirine 100 mg, Lamivudine 300 mg, Tenofovir Disoproxil Fumarate 300 mg)
Number of subjects: 734

Group type: COMPARATOR
Intervention: EFV/FTC/TDF (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil Fumarate 300 mg)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF
Number of subjects: 734

Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 734
Study: 30588965

Group type: EXPERIMENTAL
Intervention: pre‐HD preparatory program
Number of subjects: 100

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 100
Study: 26796709

Group type: EXPERIMENTAL
Intervention: Combined low‐level laser therapy (LLLT) with passive stretching exercises
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo LLLT with passive stretching exercises
Number of subjects: 48
Study: 24664198

Group type: EXPERIMENTAL
Intervention: Shoulder countertraction apparatus and physiotherapy (20 minutes a day for 5 days per week for 2 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Shoulder countertraction apparatus and physiotherapy
Number of subjects: 100
Study: 22120829

Group type: EXPERIMENTAL
Intervention: ghrelin infusion 1 ng/kg/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ghrelin infusion
Number of subjects: 20
Study: 21070103

Group type: EXPERIMENTAL
Intervention: E-learning Mental Health First Aid training
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Printed Mental Health First Aid manual
Number of subjects: 262

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 262
Study: 17382029

Group type: EXPERIMENTAL
Intervention: Dual VEGF/EGFR inhibition (e.g., erlotinib and bevacizumab, or vandetanib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual VEGF/EGFR inhibition
Number of subjects: 0
Study: 15005954

Group type: EXPERIMENTAL
Intervention: Table format presentation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Narrative format presentation
Number of subjects: 100
Study: 11782829

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation and antegrade electroejaculation for SCI group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual ejaculation for controls
Number of subjects: 30
Study: 9832490

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NO plus 50% oxygen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 14
Study: 8585507

Group type: EXPERIMENTAL
Intervention: Videotape featuring positive deaf and hard of hearing role models
Number of subjects: 0
Study: 2668787

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 and 600 mg per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 772669

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of pseudoephedrine and triprolidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30189197

Group type: EXPERIMENTAL
Intervention: BLI-bright
Number of subjects: 629

Group type: COMPARATOR
Intervention: WLI
Number of subjects: 629
Study: 28431747

Group type: EXPERIMENTAL
Intervention: Vibration training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 23
Study: 26526085

Group type: EXPERIMENTAL
Intervention: Dynamic position changes during colonoscope withdrawal
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Control group (left lateral position during colonoscope withdrawal)
Number of subjects: 1072
Study: 25127885

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 22203446

Group type: EXPERIMENTAL
Intervention: Gated single-photon emission computed tomography (SPECT)
Number of subjects: 215

Group type: COMPARATOR
Intervention: High-risk group without perfusion defect
Number of subjects: 215

Group type: COMPARATOR
Intervention: Low-risk group
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Gated SPECT added to clinical and echocardiographic variables
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 215
Study: 19390123

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose set at 80-110 mg/dL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional insulin therapy (blood glucose maintained at 180-200 mg/dL)
Number of subjects: 40
Study: 17617204

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Biliary drainage alone
Number of subjects: 26
Study: 16638996

Group type: EXPERIMENTAL
Intervention: Strip meniscometry
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tear film lipid layer interferometry
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tear film break‐up time measurement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ocular surface vital staining with fluorescein and rose bengal dyes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Schirmer‐1 test
Number of subjects: 50
Study: 12008861

Group type: EXPERIMENTAL
Intervention: Active treatment (impulse magnetic-field therapy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10493666

Group type: EXPERIMENTAL
Intervention: Prolactin (PRL) treatment of RA synovial cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhibitors of PRL release (e.g., bromocriptine)
Number of subjects: 0
Study: 8740792

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (O + D)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone plus lorazepam (M + D + L)
Number of subjects: 237
Study: 1909241

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg tds
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg tds
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg tds
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 6309637

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg b.i.d.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg t.i.d.)
Number of subjects: 45
Study: 31755917

Group type: EXPERIMENTAL
Intervention: Home-based remotely coached exercise group (n = 21)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Active control group (n = 11)
Number of subjects: 34
Study: 30235049

Group type: EXPERIMENTAL
Intervention: TRT using 1%‐transdermal T‐gel (50 mg/day)
Number of subjects: 80
Study: 27114091

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine + saline
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2% lidocaine/epinephrine + 1% ropivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2% lidocaine/epinephrine + saline
Number of subjects: 72
Study: 25904494

Group type: EXPERIMENTAL
Intervention: ≥142 PACs per 24 hours at 6 months post-ablation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PACs per 24 hours in patients with recurrence
Number of subjects: 124

Group type: COMPARATOR
Intervention: PACs per 24 hours in patients without recurrence
Number of subjects: 124
Study: 24176437

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Usual care (placebo)
Number of subjects: 9340
Study: 21430121

Group type: EXPERIMENTAL
Intervention: Parental education regarding changing to reduced-fat dairy foods
Number of subjects: 93

Group type: COMPARATOR
Intervention: Reducing screen time
Number of subjects: 93
Study: 18937999

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once weekly for 24 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 20
Study: 17456819

Group type: EXPERIMENTAL
Intervention: Ranolazine (1000 mg twice daily, initiated intravenously)
Number of subjects: 6560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6560

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 6560
Study: 15135693

Group type: EXPERIMENTAL
Intervention: Modeling group (multivariate analysis to define independent predictors of mortality)
Number of subjects: 5679

Group type: EXPERIMENTAL
Intervention: Composite score application in the validation group
Number of subjects: 5679

Group type: EXPERIMENTAL
Intervention: Independent predictors of mortality identified
Number of subjects: 5679
Study: 11137727

Group type: EXPERIMENTAL
Intervention: Nurse-led health education programme
Number of subjects: 0
Study: 9737817

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg four times daily for 21 doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diltiazem and Hydrochlorothiazide (combination)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg twice daily for 11 doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and Diltiazem (combination)
Number of subjects: 20
Study: 7812302

Group type: EXPERIMENTAL
Intervention: MVAC
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MVEEC
Number of subjects: 54
Study: 2729379

Group type: EXPERIMENTAL
Intervention: Regular coffee (454 +/- 4 mg caffeine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (12 +/- 0.4 mg caffeine)
Number of subjects: 8
Study: 31068398

Group type: EXPERIMENTAL
Intervention: CTH (Interactive Behavior Change Technology)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: CTH
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: CTH + PF (CTH plus brief practice facilitation)
Number of subjects: 488

Group type: COMPARATOR
Intervention: SMS-ED (Self-Management Support Education)
Number of subjects: 488
Study: 28490712

Group type: EXPERIMENTAL
Intervention: Tofacitinib (1 to 30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib (1 to 100 mg or 5 mg twice daily)
Number of subjects: 0
Study: 25499559

Group type: EXPERIMENTAL
Intervention: Assessment Response (AR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigation Response (IR)
Number of subjects: 0
Study: 23673101

Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg/d)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Indometacin (75 mg twice daily)
Number of subjects: 178
Study: 19832873

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 64

Group type: COMPARATOR
Intervention: Seton
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Second injection of glue
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Seton treatment after glue failure
Number of subjects: 64
Study: 19716727

Group type: EXPERIMENTAL
Intervention: Clip
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cavit‐G
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketac Molar Easymix
Number of subjects: 48

Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 48

Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 48
Study: 17477109

Group type: EXPERIMENTAL
Intervention: Blocking the mineralocorticoid receptor with anti-aldosterone agents
Number of subjects: 0
Study: 15087637

Group type: EXPERIMENTAL
Intervention: Brachial plexus nerve block with arm placed alongside body (group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brachial plexus nerve block with arm in 90 degrees abduction (group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Brachial plexus nerve block
Number of subjects: 52
Study: 11159256

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CMZ) 600 mg/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sustained-release morphine 90 mg/d
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9013163

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oxygen (placebo control)
Number of subjects: 38
Study: 7880656

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.8% glucose
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% bupivacaine with 0% glucose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.8% glucose at L2-3 interspace
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 8% glucose
Number of subjects: 80
Study: 2516615

Group type: EXPERIMENTAL
Intervention: Sorbiphos (2 g)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alu-Cap (950 mg)
Number of subjects: 5
Study: 787738

Group type: EXPERIMENTAL
Intervention: Mersyndol (analgesic/antihistamine combination containing paracetamol, codeine phosphate, doxylamine succinate, and caffeine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mersyndol (analgesic/antihistamine combination)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31803945

Group type: COMPARATOR
Intervention: SBIRT-only
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: SBIRT + Alcohol Treatment
Number of subjects: 181
Study: 31711088

Group type: EXPERIMENTAL
Intervention: Implants placed in surgically bone-grafted sites
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Presence of adjacent implants
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Overall implants
Number of subjects: 304
Study: 28246207

Group type: EXPERIMENTAL
Intervention: FOLFIRI/simtuzumab 700 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: FOLFIRI/simtuzumab 200 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: FOLFIRI/placebo
Number of subjects: 249
Study: 25294746

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change (ILS)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382

Group type: COMPARATOR
Intervention: Metformin 850 mg twice a day
Number of subjects: 382
Study: 23791258

Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MTA Plus
Number of subjects: 45

Group type: COMPARATOR
Intervention: AH Plus (Control)
Number of subjects: 45
Study: 21240170

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 1ml/kg (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 1ml/kg with clonidine 2μg/kg (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 60
Study: 19856686

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 119

Group type: COMPARATOR
Intervention: Fluid replacement therapy
Number of subjects: 119
Study: 17053946

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment after open reduction and internal fixation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (open reduction and internal fixation without shockwave treatment)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment
Number of subjects: 56
Study: 14971537

Group type: EXPERIMENTAL
Intervention: Meshed skin graft method (expansion ratio 1:3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Split thickness skin graft method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 10916098

Group type: EXPERIMENTAL
Intervention: HCTZ (50 mg) + KHCO3 (60 mmol daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: HCTZ (50 mg) + KCl (60 mmol daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: KHCO3 (60 mmol daily) alone
Number of subjects: 50
Study: 9238885

Group type: EXPERIMENTAL
Intervention: Rowenta Dentiphant powered toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral-B 20 toothbrush
Number of subjects: 0
Study: 1431574

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid diet (n = 29)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid diet (n = 29)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Trans-fatty acid diet
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Linoleic acid diet
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Trans-monounsaturates diet
Number of subjects: 173
Study: 6143514

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 30672800

Group type: EXPERIMENTAL
Intervention: Adrenalectomy for unilateral primary aldosteronism
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Predictive score based on six presurgical factors
Number of subjects: 380